193 related articles for article (PubMed ID: 28545426)
1. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
2. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
[TBL] [Abstract][Full Text] [Related]
3. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
4. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
Ahearn TU; Peisch S; Pettersson A; Ebot EM; Zhou CK; Graff RE; Sinnott JA; Fazli L; Judson GL; Bismar TA; Rider JR; Gerke T; Chan JM; Fiorentino M; Flavin R; Sesso HD; Finn S; Giovannucci EL; Gleave M; Loda M; Li Z; Pollak M; Mucci LA;
Carcinogenesis; 2018 Dec; 39(12):1431-1437. PubMed ID: 30165429
[TBL] [Abstract][Full Text] [Related]
5. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
[TBL] [Abstract][Full Text] [Related]
9. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
10. Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract][Full Text] [Related]
11. Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
Borkowetz A; Froehner M; Rauner M; Conrad S; Erdmann K; Mayr T; Datta K; Hofbauer LC; Baretton GB; Wirth M; Fuessel S; Toma M; Muders MH
Int J Cancer; 2020 May; 146(9):2619-2627. PubMed ID: 31509606
[TBL] [Abstract][Full Text] [Related]
12. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
13. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
Meisel Sharon S; Pozniak Y; Geiger T; Werner H
Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
[TBL] [Abstract][Full Text] [Related]
15. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
[TBL] [Abstract][Full Text] [Related]
16. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
18. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
19. DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
Tolkach Y; Zarbl R; Bauer S; Ritter M; Ellinger J; Hauser S; Hüser L; Klauck SM; Altevogt P; Sültmann H; Dietrich D; Kristiansen G
Am J Pathol; 2021 Apr; 191(4):618-630. PubMed ID: 33485866
[TBL] [Abstract][Full Text] [Related]
20. RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
Eryilmaz IE; Aytac Vuruskan B; Kaygısız O; Egeli U; Tunca B; Kordan Y; Cecener G
Prostate; 2019 Feb; 79(2):195-205. PubMed ID: 30294801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
